CPA Condemns Senate Gutting FEOC Excise Tax, Weakening of FEOC Prohibitions
The Senate’s decision to remove the FEOC Excise Tax and weaken FEOC restrictions is a blatant giveaway to the Chinese Communist Party’s solar industry.
Vote Alert: CPA Urges Senators to Reject Amendments to Strike, Weaken FEOC Excise Tax
Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
GM Ranked as the Most China-Exposed American Corporation
Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
CPA Supports FEOC Excise Tax in President Trump’s “One Big Beautiful Bill” to Strengthen U.S. Solar Industry and National Security
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
U.S. Kitchen Cabinet Industry Needs Support Amid Unrelenting Import Surge
The U.S. kitchen cabinet industry has a long and storied history, deeply rooted in small- to medium-sized businesses that form the backbone of American manufacturing.
CPA Warns Senate Bill Contains Dangerous “Loophole” Benefiting China’s Solar Industry
CPA warned that the Senate version of President Trump’s reconciliation bill—known as the One Big Beautiful Bill—contains a critical loophole in both the Section 48E investment tax credit and 45Y production tax credit in the Inflation Reduction Act (IRA), creating an unintended but dangerous giveaway to China’s solar industry.
How to Make Tariffs Work for National Security, Enforcement, and Revenue
The two Trump Administrations have reshaped the debate on U.S. trade policy. For the first time in decades, U.S. officials are no longer endorsing the “free trade” orthodoxy that has contributed to the erosion of its manufacturing sector. Instead, tariffs are now the centerpiece of U.S. plans to repatriate supply chains and reindustrialize America.
Rechenberg: Thanks to Imported Drugs, America Has Lost Control of Its Medicine Cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
CBO: Tariffs Bring Billions in Revenue, Barely Touch Inflation
A newly released report from the Congressional Budget Office (CBO) has upended the way policymakers should think about tariffs.
America’s Drug Shortage Isn’t a Supply Problem—It’s a Production Crisis
In the U.S. today, frontline cancer treatments are being rationed. ERs are short on sedatives. Amoxicillin—one of the most prescribed antibiotics in the country—has been in critical shortage. These are not temporary disruptions. They reflect a structural breakdown caused by the erosion of America’s pharmaceutical manufacturing base and a decades-long surge in generic drug imports.
